Company: KROS
Filing Date: 2025-04-23
Form Type: DEF 14A
Source: 0001104659-25-037982
Chunk: 85

Company: Keros Therapeutics, Inc.
Filing Date: 2025-04-23
Form: DEF 14A
Chunk 85
---
1, 2024. (2) Amounts reported represent the aggregate grant date fair value of stock options granted to our non-employee directors during 2024 under our 2020 Plan, computed in accordance with ASC Topic 718, excluding the effect of estimated forfeitures. The assumptions used in calculating the grant date fair value of the stock options reported in this column are set forth in the notes to our audited financial statements included in our Annual Report on Form 10-K for the year ended December 31, 2024. These amounts do not reflect the actual economic value that will be realized by the non-employee directors upon vesting of the stock options, the exercise of the stock options, or the sale of the common stock underlying such stock options. (3) The table below sets forth the aggregate number of shares underlying outstanding stock options held by each non-employee director as of December 31, 2024. None of our non-employee directors held other unvested stock awards as of December 31, 2024.

| Name                  | ​ | ​ | Number of SharesUnderlying Options |   |        |   | ​ |
| Jean-Jacques Bienaimé | ​ | ​ | ​                                  | ​ | 17,600 | ​ | ​ |
| Nima Farzan           | ​ | ​ | ​                                  | ​ | 45,086 | ​ | ​ |
| Carl L. Gordon        | ​ | ​ | ​                                  | ​ | 36,586 | ​ | ​ |
| Mary Ann Gray         | ​ | ​ | ​                                  | ​ | 53,173 | ​ | ​ |
| Tomer Kariv           | ​ | ​ | ​                                  | ​ | 36,586 | ​ | ​ |
| Julius Knowles        | ​ | ​ | ​                                  | ​ | 36,586 | ​ | ​ |
| Ran Nussbaum          | ​ | ​ | ​                                  | ​ | 36,586 | ​ | ​ |
| Alpna Seth            | ​ | ​ | ​                                  | ​ | 40,000 | ​ | ​ |

(4) Mr. Bienaimé joined our Board and each committee on which he serves in June 2024. Dr. Seehra, our Chief Executive Officer, is also the Chair of our Board but does not receive any additional compensation for his service as a director. See the section titled “Executive Compensation” for more information regarding the compensation earned by Dr. Seeh